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KDM1A inhibition enhances chemotherapy response in glioblastoma
Moraima Rodriguez Guerrero, Bridgitte Palacios, Gangadhara R. Sareddy
Department of Obstetrics & Gynecology, University of Texas San Antonio, Health Careers High School

Introduction

Fig. 1. Conﬁrmation of KDM1A-KO and KD in GBM cells
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Fig. 2 A, U251 control and KDM1A-KO cells were treated with various amounts
of TMZ for 7 days, and the cell viability was determined using MTT assays. B,
T98G cells expressing control shRNA or KDM1A-shRNA were treated with
varying amounts of TMZ for 7 days and the cell viability was determined using
MTT assays.
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Fig. 4. Knockout of KDM1A reduced the
expression of DNA repair genes in GBM cells
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Glioblastomas (GBM) have dismal survival rates
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of 1 year – 34.6% and 5 years – 4.75% which
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external beam radiation therapy, adjuvant
K
C
chemotherapy with temozolomide (TMZ), and
KDM1A
tumor treating ﬁelds. Regardless of the extensive
therapy, patients will eventually fall victim to this
β-Actin
deadliest disease. Deregulated oncogenic and
epigenetic signaling mechanisms contribute to
T98G
chemo and radiation therapy resistance. The
U251
lysine-speciﬁc demethylase-1 (KDM1A/LSD1)
demethylates both mono- and dimethylated lysine
residue-4 and -9 speciﬁcally on histone H3. Fig 1 A, Knockdown of KDM1A in T98G was tested using western blotting.
KDM1A regulates gene expression programs by B, Knockout of KDM1A in U251 was tested using western blotting.
changing the epigenetic histone marks at the gene
prompters. Emerging studies have shown that
KDM1A is overexpressed in glioblastoma and Fig. 3. KDM1A-KO and –KD enhanced the TMZ eﬃcacy in
other cancers. However, the role of KDM1A in cell survival
therapy resistance of GBM remains unknown. In
Vehicle
TMZ (10 uM)
this study, we tested the hypothesis that KDM1A
A
inhibition sensitizes GBM to TMZ therapy.

Fig. 2. KDM1A-KO and –KD sensitize TMZ-sensitive and
TMZ-resistant GBM cells to TMZ treatment

The objective of this study is to test the eﬃcacy of
KDM1A inhibition on chemotherapy sensitization
of glioblastoma cells.
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Methods

Fig. 4 A, Expression of DNA repair and apoptosis genes in
U251 or KDM1A KO was analyzed using RT-qPCR
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To study the role of KDM1A in GBM cells, we
have generated KDM1A knockout (KDM1AB
KO) cells and KDM1A-shRNA transfected
GBM cells (KDM1A-KD). Conﬁrmation of
these knockdowns and knockouts was done
using western blotting. The eﬀect of
KDM1A-KO and –KD on cell viability and
survival of U251 and T98G cells was studied
using MTT cell viability assays and clonogenic
cell survival assays respectively. A mechanistic
study was conducted using RT-qPCR which
Fig. 3 A, U251 or KDM1A-KO cells were treated with TMZ for 5 days and cell survival was
examined the expression of DNA repair genes in
determined after 14 days using colony formation assays. B, T98G control shRNA or
U251 and U251 KDM1A-KO GBM cells.

KDM1A-shRNA cells were treated with TMZ for 5 days and cell survival was determined after
14 days using colony formation assays.

Results
Western blot analysis conﬁrmed the knockout and knockdown of
KDM1A in GBM cells. Cell viability assays showed that KDM1A
knockout or knockdown potentiated the cytotoxic eﬀect of TMZ in TMZ
sensitive and TMZ resistant GBM cells. Further, clonogenic survival
assays demonstrated that KDM1A knockout or knockdown enhanced
the TMZ eﬃcacy in reducing the cell survival of GBM cells.
Importantly, qRT-PCR assays showed that KDM1A knock out reduced
the expression of DNA repair genes and induced the apoptotic gene p21.

Conclusion
Our results provided the evidence that knockout or knockdown of
KDM1A sensitizes GBM cells to chemotherapy and may lead to the
development of KDM1A inhibitor therapy in conjunction with TMZ.
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This research was conducted at The University of Texas Health Science Center in San Antonio,
TX over the course of 9 months under the supervision of Dr. Gangadhara Sareddy. This study is
based on the hypothesis that the protein KDM1A could increase chemotherapy response in
glioblastoma (brain cancer) when inhibited. When conducting this research, we had the previous
knowledge that a protein known as KDM1A was related to chemotherapy response in
glioblastoma due to previous research done by Dr. Sareddy in 2017 which indicated that
KDM1A inhibition induced cell death in glioblastoma stem cells via unfolded protein response
pathway (as seen in article 4 in the bibliography). This along with other studies that connected
the inhibition of KDM1A and cell death in glioblastoma cells, allowed us to develop the
hypothesis that when exposed to different levels of chemotherapy and KDM1A inhibition, there
would be an increase in the response level of the glioblastoma cells, meaning more cell death
would be seen. The way we went about testing this was first identifying certain glioblastoma cell
lines we wanted to work with, which ended up being U251 and T96G. U251 is considered a very
weak cell line and easy to kill while T98G is a rather difficult cell line to kill. We wanted to see
two different ends of the spectrum and decided that these two commercial cell lines would be
appropriate. Once we identified the cell lines we wanted to work with, we inhibited KDM1A
using a virus and then tested the cell lines using western blot in order to ensure that the protein
was inhibited. As seen in figure 1 both cell lines had the KDM1A “knockout” or “knockdown”
which is just another way of saying the protein is no longer active. Western blot confirmed this
by showing a lack of bands present in the KDM1A knockdown/knockout cell lines. After

confirming this knockdown/knockout we began by exposing the cell lines to different levels of a
chemotherapy called temozolomide (TMZ) and comparing those results to the regular cell lines.
As seen in figure 2, there was a decrease in the amount of cell viability in the knocked out/down
cell lines. This was done by conducting a MTT assay which is way to expose a cell line to
multiple levels of something in one trial. After repeating the experiment multiple times, we
determined that the next step in our journey was to have a visible representation of cell survival
rates. So in order to do that we conducted colony formations, which showed us how many cell
colonies formed over a week when exposed to TMZ. We did this with both the regular cell lines
and the knockdown/out cell lines. As seen in figure 3, there was a significant decrease in the
amount of cell colonies formed when compared to the vehicle plates. With all this evidence after
multiple trials we could then say that there was a definite increase in response to chemotherapy
when KDM1A was inhibited. Even then we wanted to test the function of the cell when KDM1A
was inhibited, so we used a test called RT-qPCR in order to determine how well DNA repair
genes and cell death genes were being used in the cell lines. As seen in figure 4, there was a
significant decrease in the function of both RAD51 and MRE11A which are both DNA repair
genes. As well as a significant increase in the P21 genes which is a cell death gene, which means
that more cells were dying and less were being repaired by the genes. With all of this evidence,
we were able to conclude that knockout or knockdowns of KDM1A sensitized glioblastoma cells
to chemotherapy and may lead to the development of KDM1A inhibitor therapy in conjunction
with chemotherapy.

